While the feasibility of whole human genome sequencing was proven by the success of the Human Genome Project several years ago, the prevalence of personal genome sequencing in the medical industry is still elusive due to its unrealistic cost and time requirements. Microeqisastartupcompanywiththegoalofovercomingtheselimitationsbysequencingaminimumof12completehumangenomesperdayatanerrorratelessthantenpartsinmillionataprofitablemarketpriceoflessthanUS1000 per genome. To overcome the technology bottlenecks hindering current biotech companies from achieving these target throughput, error rate, and market price goals, Microeqhasdevelopedaninnovativesequencingtechniquethatusesshortreadfragmentswithhighcoverageonamicrofluidicsplatform.Short,amplifiedDNAfragmentsaregeneratedfromaninputofcustomersaliva.6basepair(bp)sequencehybridizationisusedforsequencingeachoftheDNAfragmentsindividually.TheresultsarethesehydridizationreadsarethenassembledviadeBruijngraphtheoryandthegraphicalreconstructionsofeachfragment’ssequencearethenassembledtoacompletegenomeviashotgunsequencingwithanexpectederrorratelessthan1in100,000bp.Uponthecompletionoffinancialanalysis,bothasmall−scalebusinessmodelproducing72genomesperdayatUS999 per genome, and a largescale business model producing 52.2 genomes per year at a market price of US299pergenomewerefoundtobeprofitable,yieldingMicroeq investors return margins of ~90% and 300% for the small and large scale models, respectively. With a market price Micro$eq offers personal genome sequencing at one-tenth of its nearest potential competitor’s cost. Additionally, its ability for bulk-sequencing allows it to profitably venture into the previously untapped Pharmaceutical Industry market sector, enabling the creation of large-scale genome databases which are the next step forward in the quest for truly personalized